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 MIF plays a key part in inflammatory diseases and cancer 
 Many structural scaffolds are available for MIF inhibition 
 Not all studies provide proper assessment of MIF inhibitory potency 













Teaser: Increasing evidence indicates the value of macrophage migration inhibitory factor 
(MIF) as a drug target in inflammatory diseases and cancer. This review provides an overview 
of small-molecule MIF inhibitors and indicates future developments. 
 
Macrophage migration inhibitory factor (MIF) is an important cytokine for which an 
increasing number of functions is being described in the pathogenesis of inflammation 
and cancer. Nevertheless, the availability of potent and druglike MIF inhibitors that are 
well-characterized in relevant disease models remains limited. Highly potent and 
selective small-molecule MIF inhibitors and validation of their use in relevant disease 
models will advance drug discovery. In this review, we provide an overview of recent 
advances in the identification of MIF as a pharmacological target in the pathogenesis of 
inflammatory diseases and cancer. We also give an overview of the current 
developments in the discovery and design of small-molecule MIF inhibitors and define 
future aims in this field. 
 















Despite its discovery over 50 years ago in 1966 [1,2], the functions of the cytokine 
macrophage migration inhibitory factor (MIF) have still not been fully elucidated. Initially, 
MIF was identified as a T-cell-derived mediator that inhibits random movement of 
macrophages. Its activity was found to correlate with delayed-type hypersensitivity reactions, 
a prominent feature of several chronic diseases in humans [2]. In addition, MIF is released at 
sites of infection, causing macrophages to concentrate and carry out antigen processing and 
phagocytosis [3]. Today, MIF is recognized as a crucial player in innate immune responses 
that has a role in multiple diseases [4,5]. Therefore, the development of small-molecule MIF 
inhibitors that inferfere with its functions is quickly gaining importance. 
The human MIF gene was cloned and expressed for the first time in 1989 [6]. MIF is a 
relatively small protein that consists of 114 amino acids and has a molecular mass of 12 345 
Da. Structural analysis of MIF revealed its striking similarities to bacterial enzymes from the 
tautomerase superfamily. Searching the human genome indicated that D-dopachrome 
tautomerase (D-DT) is the other gene with marked homology to MIF. Owing to this similarity, 
D-DT is also referred to as MIF2 and an overlapping functional spectrum for MIF and D-DT 
has been suggested [7]. This should be considered in the evaluation of MIF cytokine activities 
and in the development of small-molecule MIF modulators. 
MIF, a member of the tautomerase superfamily [8], is found across various organisms 
including bacteria, mice, plants, protozoa, helminths, molluscs, arthropods and fish [9–11]. 
These tautomerase family members have similar enzyme activity involving an amino-acid-
terminal proline that acts as a general base in keto-enol tautomerisation reactions of α-keto-
carboxylates. In addition to its cytokine activity, MIF harbors keto-enol tautomerase and low-
level dehalogenase activity, providing a functional link to other members of the tautomerase 
family [10]. MIF is a homotrimeric protein in which three monomers associate to form a 
symmetrical trimer (Figure 1a). Each MIF trimer has three tautomerase active sites at the 
interfaces of the monomer subunits. Characteristic for this family, MIF has an N-terminal 
proline (Pro-1), which is located within a hydrophobic pocket [12]. The residue Pro-1 was 
shown to be conserved between MIF and its bacterial homologs. Moreover, other invariant 
residues were identified as being clustered around the N-terminal proline. The evolutionary 
preservation of this region suggests its importance in the biological function of MIF [13]. 
Despite the lack of a known physiological substrate, it was shown that D-dopachrome (a 
stereoisomer of naturally occurring L-dopachrome), phenylpyruvate and p-
hydroxyphenylpyruvate are accepted as substrates by MIF (Figure 1b) [14,15]. A crystal 
structure of MIF in complex with p-hydroxyphenylpyruvate demonstrated that Pro-1 
functions as a catalytic base in the tautomerase reaction [16]. It is well recognized that the 
currently defined substrates of MIF either do not exist naturally in vivo or do not exist at 
significant concentrations required for biological activity [17]. Nevertheless, small-molecule 
modulators of MIF tautomerase activity could have an impact on MIF cytokine activity owing 












Although MIF tautomerase activity might not be directly linked to its cytokine 
activity, it provides an opportunity for efficient screening of compound collections that could 
provide molecules that interfere with MIF cytokine activity. One of the best known targets to 
mediate MIF cytokine activity upon binding is the cluster of differentiation 74 (CD74) 
receptor [18]. Interestingly, recent findings demonstrate that MIF binding to CD74 occurs in 
the vicinity of the MIF tautomerase active site, which supports the idea that MIF tautomerase 
inhibitors could have potential to interfere with MIF cytokine function [19]. In this 
perspective, robust assays to test the ability of MIF tautomerase inhibitors to interfere with 
MIF cytokine functions in vitro and in vivo are highly important. 
Functional cytokine roles of MIF and D-DT have been described in innate and 
adaptive immune responses [7,13]. It has been shown that MIF stimulates the production of 
proinflammatory mediators such as tumor necrosis factor (TNF)α, interferon (IFN)γ, 
interleukin (IL)-1β, IL-2, IL-6 and IL-8 and other effector cytokines [13]. The MIF–CD74 
interaction is well known to initiate subsequent signaling cascades leading to cellular 
responses [18]. The biological functions of the CD74 receptor in immune diseases has 
recently been reviewed by Su et al. [20]. With respect to CD74 binding it is interesting to note 
that a difference has been reported between MIF and D-DT in a study by Merk et al. [21]. The 
same study indicates that MIF has a steeper dose:response ratio for macrophage migration 
inhibition and glucocorticoid overriding. This suggests an immune downregulatory role for D-
DT in the presence of MIF. By contrast, a recent study demonstrated that MIF and D-DT are 
connected to disease progression of multiple sclerosis subjects [22]. This study and other 
studies as reviewed by Merk et al. [7] and O’Reilly et al. [23] indicate an overlapping activity 
spectrum for both cytokines. 
Apart from the CD74 receptor, MIF can also bind to chemokine receptors such as 
CXCR2, CXCR4 and CXCR7 to induce inflammatory and immune cell chemotaxis [24,25]. 
Given the proinflammatory activities, MIF is implicated in acute and chronic inflammatory 
diseases such as asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, 
sepsis, diabetes, atherosclerosis and cardiovascular diseases [13]. Many studies have 
investigated MIF as a biomarker for various diseases that have an inflammatory component, 
including systemic infections and sepsis, cancer, autoimmune diseases and different metabolic 
disorders, suggesting its important role in these diseases [26]. It should also be noted that MIF 
has been demonstrated to be posttranslationally modified and that these modifications affect 
its biological functions [27]. MIF, but not D-DT, has a CXXC motif that can be oxidized to an 
intramolecular disulfide bond. Oxidized MIF has also been proposed as a biomarker for 
different diseases [28]. Other studies indicate that oxidized MIF is the disease-related 
conformational isoform that could be employed for diagnosis and therapy [29,30]. It is to be 
expected that MIF redox behavior interferes with binding of small-molecule inhibitors. 
However, little is known about the structural consequences of these modifications in relation 
to inhibitor binding. Therefore, this represents an interesting and novel line of investigation. 
Despite extensive studies on the functional role of MIF in multiple disease models, the 
identification and validation of the functional consequences of small-molecule MIF 
tautomerase inhibitors is still at an early stage. The effects of such inhibitors have been 
investigated using the long-known standard MIF antagonist ISO-1 (Table 1) in in vitro assays 












on human disease are still observational [32], which indicates a need for further validation of 
MIF as a drug target. In this review, we aim to provide an overview of recent advances in the 
identification of MIF as a pharmacological target in the pathogenesis of inflammatory 
diseases and cancer (Figure 1c). Based on that, we will provide an overview of the current 
developments in the disovery and design of small-molecule MIF inhibitors and define future 
goals in this field. 
 
The role of MIF in pathogenesis of inflammatory diseases 
 
Acute inflammation is a protective, beneficial and self-limiting process during innate immune 
responses, but chronic inflammation is maladaptive and can result in tissue injury and 
dysfunction. For instance, some studies have shown that MIF plays an important part in the 
pathology of bladder inflammation. In bladder tissue substance P, an important inflammatory 
mediator, increases the levels of MIF. The important role of MIF was subsequently shown by 
administration of an anti-MIF antibody that could decrease substance-P-induced inflammatory 
changes in the bladder [33]. MIF was also shown to play a part in worsening of lung 
inflammation. High levels of MIF were reported to be detrimental for survival in a mouse 
model of pneumococcal pneumonia. Treatment of mice with a small-molecule inhibitor of 
MIF, designated MIF098 (Alissa-5) (Table 2), improved survival by reducing inflammatory 
responses [34]. In addition, higher MIF levels were produced by alveolar macrophages in a 
mouse model for COPD as compared with those from healthy mice, and inhibition of MIF 
function by ISO-1 could block the corticosteroid-insensitive lung inflammation [35]. 
MIF also acts as an essential mediator of host immunity against various bacterial 
infections; however, its persistent or recurrent expression during chronic inflammatory 
disease stages can lead to loss of function and mortality. The involvement of MIF in the 
enhancement of biofilm formation by Pseudomonas aeruginosa was shown by the use of 
SCD-19, a small-molecule inhibitor targeting MIF tautomerase activity. Application of this 
inhibitor resulted in lower bacterial burden in a mouse model of this infection as compared 
with untreated mice [36]. As another example, MIF promotor polymorphisms resulting in 
high MIF levels in cerebrospinal fluid of patients with streptococcal meningitis correlated 
with systemic complications and death [37]. Moreover, the authors of this study showed a 
reduction in bacterial load in a mouse model of pneumococcal pneumonia and sepsis after 
treatment with an anti-MIF antibody. From these studies it becomes clear that MIF plays a 
part in biofilm formation and mortality during bacterial infections, and it provides initial 
evidence that targeting MIF with small-molecule inhibitors has potential to interfere with such 
pathological conditions. 
A relationship of MIF with autoimmune inflammatory disease has been observed in 
experimental autoimmune myocarditis. Early treatment of this disease with an anti-MIF 
antibody markedly delayed the onset of, and significantly reduced the severity of, this disease 
in rats [38]. The importance of MIF in the autoimmune inflammatory process has also been 
demonstrated for rheumatoid arthritis. It was observed that treatment with an anti-MIF 
antibody before immunization with type II collagen leads to delayed onset of arthritis in a 












correlates with disease severity in autoimmune inflammatory diseases and that treatment with 
anti-MIF antibodies has beneficial effects. 
 
The role of MIF in cancer pathogenesis 
 
Inflammation and immunity have key roles in the onset and progression of cancer. Persistent 
or recurrent inflammation is related to development of cancer. By contrast, anticancer 
immune responses counteract the development and progression of cancer. From this 
perspective, the functional output of MIF as a key cytokine of the immune system can be 
connected to various aspects of oncology [40]. High serum levels of MIF are seen in cancer 
patients and tissues and MIF has consequently been proposed as a biomarker. In addition, 
high MIF levels correlate with poor prognosis in various carcinomas. Besides being involved 
in angiogenesis and thus indirectly in promoting tumour growth, the interaction of MIF with 
its receptors has been shown to initiate cancer-promoting signal transduction pathways. For 
example, binding of MIF to CD74 can lead to stimulation of the ERK1/2 but also PI3K/AKT 
pathways and binding of MIF to the CXCR4 receptor was suggested to induce metastases 
[41]. 
Involvement of MIF in the development of prostate cancer was shown by studies with 
an androgen-independent prostate cancer cell line. In these studies, inhibition of MIF by ISO-
1, anti-MIF antibody or MIF siRNA resulted in decreased cell proliferation. ISO-1 
significantly decreased tumor volume and tumor angiogenesis [42]. In another study with a 
prostate cancer cell line, treatment with anti-MIF antibodies was reported to reduce cell 
growth and, in a xenograft mouse model of prostate cancer, anti-MIF antibodies were shown 
to limit tumor growth [43]. The involvement of MIF in the development of bladder cancer has 
also been described. MIF was reported to promote in vitro and in vivo bladder cancer 
progression via increasing cell proliferation and angiogenesis. The orally available MIF 
inhibitors CPSI-2705 and CPSI-1306 (Table 2) have been shown to effectively decrease the 
growth and progression of bladder cancer in vivo [44].  
A study on the role of MIF in the development of colon cancer in patients reported a 
positive correlation between MIF serum concentrations and colorectal cancer severity [45], 
thus indicating a potential use of MIF as a biomarker. The same study demonstrated in a 
mouse model with colon carcinoma cell transplants that treatment with MIF inhibitor ISO-1 
or anti-MIF antibodies resulted in a significant reduction of the tumor burden, thus indicating 
a potential use of MIF-directed therapeutics in cancer. Furthermore, MIF has been indicated 
to be involved in the progression of lung cancer. Blocking the hydrophobic pocket that 
harbours MIF tautomerase activity, by a small-molecule inhibitor of the isocoumarin class, 
SCD-19 (Table 2), which significantly attenuated lung cancer growth [46]. Taken together, 
these studies demonstrate a positive correlation between MIF and the progression of cancer. 
Application of small-molecule MIF inhibitors or anti-MIF antibodies attenuated cancer 
growth, thus indicating the potential of anti-MIF therapeutics in cancer [47–49]. 
 













Because of the essential involvement of MIF in the progression of numerous disorders with an 
inflammatory component, it is not surprising that attempts were made to find MIF-directed 
therapeutics. One line of development is the application of biologics, such as anti-MIF 
antibodies, as novel therapeutics. This approach has been used in many proof-of-concept 
studies [33,38,39,42,43,45]. One clinical trial with an anti-MIF antibody has been reported, 
however no results have been revealed yet [50]. The other line of development is to generate 
MIF-binding small molecules with the aim to interfere with MIF functions. To develop MIF 
inhibitors, many studies resort to evaluating interference with MIF tautomerase activity. In 
this perspective, the evaluation of MIF tautomerase inhibitors for their interference with MIF 
cytokine functions in relevant disease models is highly important. Compared with biologicals, 
small-molecule MIF inhibitors offer advantages such as lower manufacturing costs, 
nonimmunogenic reactions and the possibility of oral administration. Therefore, this route of 
exploration gained tremendous interest. Here, we summarize the currently identified MIF 
tautomerase inhibitors and discuss their SAR. Inhibitors containing a chromen-4-one scaffold 
were identified in 2001 and their Ki values range between 0.04 and 7.4 µM. The most potent 
compound of this class is Orita-13 with a Ki of 0.04 µM [51]. However, a later investigation 
reported Ki values in the range of 13–22 µM for Orita-13 [52]. The phenol functionality in 
Orita-13 is also found in the MIF tautomerase substrates D-dopachrome and p-
hydroxyphenylpyruvate and proved to be a succesfull design motif for MIF inhibitors (Table 
1). 
 
Isoxazolines as MIF inhibitors 
The most frequently used reference inhibitor for MIF tautomerase activity is ISO-1, which 
was discovered in 2002. This inhibitor of the isoxazoline class was reported to inhibit MIF 
tautomerase activity in a dose-dependent manner. It binds at the same position as the substrate 
p-hydroxyphenylpyruvate with an IC50 of about 7 µM [53]. A later study described a Ki of 24 
µM for inhibition of MIF tautomerase activity [52]. A MIF–CD74 binding study reported a 
maximum of 40% inhibition at 10 µM (Table 1) [54]. Further studies showed that inhibition 
of MIF by ISO-1 in a mouse model significantly reduced prostate cancer [42] and colon 
cancer [45] and blocked melanoma cell growth [55]. Another study in a mouse model showed 
that this MIF inhibitor blocks corticosteroid-insensitive lung inflammation [35]. In addition, 
ISO-1 was also reported to inhibit MIF activity in a mouse model of type 1 diabetes and to 
result in the delayed onset of this disease [56]. Altogether, ISO-1 is a valuable compound that 
is widely used as a reference inhibitor in the initial validation of small-molecule MIF 
tautomerase inhibitors as potential therapeutics in diseases with an inflammatory component. 
Another small-molecule MIF tautomerase inhibitor with an isoxazoline scaffold is 
CPSI-1306 (Table 2). This inhibitor lacks the characteristic phenol functionality, which is 
advantageous for applications in vivo. Phenol functionalities are generally considered to be 
nondruglike because they are prone to Phase II bioconjugation reactions, thus resulting in 
quick inactivation and excretion in in vivo experiments. Oral administration of this inhibitor 
resulted in less severe symptoms in a mouse model for multiple sclerosis as compared with 
untreated mice [57]. Further small molecules with the same scaffold were synthesized and 
evaluated for MIF-inhibitory activity. The IC50 of the most active compound, Alam-4b (Table 












cell viability assay [58]. Subsequently, in 2014, another small-molecule inhibitor from the 
isoxazoline class, ISO-66 (Table 1), was reported. Its IC50 in the MIF tautomerase assay was 
1.5 µM and long-term administration of ISO-66 in a mouse model of colon cancer or 
melanoma was shown to be nontoxic and to decrease tumor burden significantly [59]. Thus, 
studies on MIF inhibitors with an isoxazoline scaffold demonstrate that the development and 
application of small-molecule MIF inhibitors has the potential to provide novel therapeutics.  
 
1,2,3-Triazoles as MIF inhibitors 
In 2010, 1,2,3-triazole derivatives were reported as inhibitors of MIF. The most potent 
compounds, Jorgensen-3g and Jorgensen-3h (Table 1), showed IC50 values of ~1 µM for MIF 
tautomerase activity and MIF-CD74 binding [60]. Subsequently, in 2015, improvements were 
made by the synthesis of several optimized biaryltriazoles. This provided potent compounds 
with a phenolic hydroxyl group that binds to the MIF tautomerase active site. Neverthless, 
some compounds had limited water solubility. The activity of this class of compounds was 
further improved by the addition of a fluorine atom adjacent to the phenolic hydroxyl group to 
enhance the H-bond interaction with residue Asn-97 of MIF. This yielded the most potent 
compound, Dziedzic-3bb (Table 1), having a Ki value of 0.057 µM and a solubility that is in 
the normal range for orally avialable drugs [61]. The synthesis of fluorescently labeled MIF 
inhibitors with a biaryltriazole scaffold was described in 2016. These inhibitors were used in a 
fluorescence polarization assay to assess the direct binding of inhibitors to the active site of 
MIF. The two most potent inhibitors, denoted Cisneros-3i and Cisneros-3j, were reported to 
have Ki values of 0.057 and 0.034 µM in the tautomerase assay and Kd values of 0.071 and 
0.063 µM in the fluorescence-polarization-based binding assay (Table 1) [62].  
 
Covalent MIF inhibitors 
The specific reactivity of the proline in the MIF active site provides opportunities to develop 
covalent inhibitors. In 2008, a compound of the phenyl-pyrimidine class, 4-IPP (Table 2), was 
reported to inactivate the MIF catalytic function by dehalogenation and formation of a 
covalent bond between C-4 of pyrimidine and the N-terminal nitrogen of Pro-1 in the MIF 
tautomerase active site. This compound also inferferes with the biological functions of MIF as 
it was reported to irreversibly inhibit lung adenocarcinoma cell migration and anchorage-
independent growth [63]. Later on, it was described that 4-IPP inhibits the growth of thyroid 
cancer cells by inducing apoptosis and mitotic cell death [64]. In 2009, isothiocyanates were 
discovered as irreversible MIF tautomerase inhibitors. The isothiocyanate BITC (Table 2) was 
shown to covalently modify the Pro-1 residue in the MIF active site. This drastically alters the 
MIF tertiary structure and results in loss of its tautomerase activity and in inhibition of MIF 
binding to CD74 [65]. 
Woodward’s reagent K is a classical heterocyclic electrophile with a specific reactivity 
[66,67]. Taking advantage of the specific reactivity of Woodward’s reagent K, covalent MIF 
inhibitors were developed. These inhibitors were shown to react with the active site Pro-1 of 
MIF and were applied for covalent labeling of MIF which proved to be selective. The 
covalent inhibitors were used as probes for labeling and imaging of MIF activities in living 
cells [68]. These examples demonstrate that it is possible to develop covalent active-site-












great potential for labeling and imaging of enzyme activity in vitro and in vivo. In contrast to 
their application in imaging, covalent inhibitors are not preferred in pharmacotherapy owing 
to concerns about their off-target effects. 
 
Other types of MIF inhibitors 
Apart from the isoxazolines and 1,2,3-triazoles, other types of reversible MIF inhibitors were 
also developed. In 2006, MIF inhibitors with a benzoxazinone scaffold were described and 
patented. The most potent compound, NVS-2, was reported to have an IC50 of 0.020 µM 
(Table 2) [69]. A later assay by Cisneros et al. reported a similar value for the Ki of 0.027 µM 
in the tautomerase assay and a Kd of 0.055 µM in the fluorescence-polarization-based binding 
assay [62]. Subsequently, in 2010, substituted benzoxazol-2-ones were discovered as MIF 
antagonists (Table 2). One potent inhibitor from this class, MIF098 (Alissa-5) showed 
noncovalent inhibition in the MIF tautomerase assay, with an IC50 of ~0.010 µM. This 
inhibitor was further reported to attenuate MIF-dependent ERK phosphorylation in human 
synovial fibroblasts, which demonstrates possible use of MIF inhibition as a therapy in 
rheumatoid arthritis [70]. 
In 2012, an allosteric MIF tautomerase inhibitor p425 was identified in an HTS of a 
library consisting of 230 000 small molecules. However, this compound is a sulfonated azo 
compound (also known as pontamine sky blue) that has poor druglike properties [71]. 
Another study, in 2016, reported inhibitor K664-1 (Table 2) with a pyrimidazole scaffold as a 
novel MIF inhibitor with an IC50 of 0.16 µM in the MIF tautomerase assay [72]. This inhibitor 
provided protection to β cells from cytokine-triggered apoptosis in a mouse model, which 
demonstrates its potential for the prevention of diabetes progression [73]. 
In 2016, compound T-614 (also known as iguratimod) was found to selectively inhibit 
MIF in vitro and in vivo. The compound has synergic effects with glucocorticoids to slow 
disease progression in a mouse model of multiple sclerosis. The IC50 of that compound in the 
MIF tautomerase assay was 6.81 µM (Table 2) [72]. Recently, novel types of MIF inhibitors 
were discovered using substitution-oriented screening (SOS). Inspired by the known 
chromen-4-one inhibitor Orita-13, a focused collection of compounds with a chromene 
scaffold was screened for MIF binding. In this study, inhibitors denoted Kok-10 and Kok-17 
(Table 2) provided IC50 values in the low micromolar range (18 and 6.2 µM, respectively) in 
the MIF tautomerase assay. The binding proved to be reversible and the enzyme kinetics 
suggested no direct interaction of these compounds with the substrate-binding pocket [74].  
 
Future perspectives of inhibitor development 
Altogether it can be concluded that a diverse array of structures can be employed to develop 
MIF inhibitors that interact with MIF tautomerase activity via direct competition, via 
allosteric modulation of substrate binding or via covalent binding. These provide valuable 
starting points to design novel structural motifs that can be employed to interfere with MIF 
cytokine functions. Inhibitors of the enzymatic activity of MIF should also be evaluated in 
assays for binding to the cellular receptors such as CD74, CXCR2, CXCR4 and CXCR7 
and/or in disease models.Within this context it is important to note that a study by Cisneros et 
al. in 2016 demonstrated that the reported IC50s of MIF tautomerase inhibitors were often not 












pointed out, for covalent or slow-tight-binding inhibitors the IC50s are time dependent. 
Therefore, it is important to evaluate the reversibility of binding by recovery of enzyme 
activity in, for example, dilution experiments [75], which is too often neglected. Another 
complicating factor is the enzyme kinetics of the MIF tautomerase activity for its substrate p-
hydroxyphenylpyruvate (4-HPP), which provides a sigmoidal curve that cannot be fitted to a 
simple one-to-one binding model. Thus, the Michaelis–Menten constant Km cannot be derived 
easily and one needs to resort to Khalf,app [74] or [S]0.5 [16]. This issue complicates the 
calculation of the equilibrium constant for inhibition (Ki) from IC50 values. Therefore, we 
argue to include enzyme dilution experiments and enzyme kinetic studies, or direct binding 




MIF has been described to have a key role in the pathogenesis of inflammatory diseases and 
cancer. Small-molecule inhibitors of MIF have been developed and used in studies to 
investigate the biological role of MIF. Inhibitor ISO-1 is widely used as a reference 
compound for MIF inhibition in mouse models of lung inflammation, prostate cancer, colon 
cancer, melanoma and diabetes. Other small-molecule inhibitors also provided positive effects 
in various disease models. Altogether this indicates the potential of MIF inhibitors for 
development of novel therapeutics for diseases with an inflammatory component.  
It is commonly presumed that MIF inhibitors identified in a MIF tautomerase assay 
have potential to interfere with MIF cytokine functions. Following this hypothesis, several 
classes of MIF tautomerase inhibitors have been identified. The isoxazolines and the 1,2,3-
triazoles are important classes of inhibitors from which potent MIF inhibitors were identified. 
Also, covalent inhibitors that react with the active site Pro-1 of MIF have been identified and 
in one case used for activity-based labeling of MIF in living cells. Over time, an increasing 
number of MIF inhibitors has been described, thus providing more insight in SAR for MIF 
binding. A complicating factor in the analysis of MIF inhibitors proved to be covalent or 
slow-tight-binding behavior that results in overestimation of the inhibitor potency. Also, the 
sigmoidal enzyme kinetics for MIF tautomerase activity complicates analysis of MIF binding. 
We argue that anticipation of these issues is needed for successful further development of the 
field. Ultimately, the identification of potent MIF inhibitors with favorable properties for drug 
discovery programs will enable the identification of novel therapeutics that target MIF 
functions in diseases with an inflammatory component. Furthermore, attention should be 
given to the MIF structural homolog D-DT, which has been demonstrated to have an 
overlapping functional spectrum of action. This suggests that the combined or separate 
therapeutic targeting of D-DT and MIF could have additional advantages. 
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Figure 1. (a) Crystal structure of macrophage migration inhibitory factor (MIF), showing that three monomers 
associate to form a symmetrical homotrimer (PDB 1CA7). (b) MIF catalyzes the tautomerisation of α-keto-















Table 1. MIF inhibitors with a phenol functionality as the key structural element that presumably binds to 
the active-site residue Asn-97 of MIF 
Abbreviations: TA, tautomerase assay; BA, binding assay MIF-CD74. 
  





Ki = 0.04 [51] (TA), 
Ki = 17 [61] (TA), 






IC50 = 7 [53] (TA), 
IC50 = 24 [52] 
(TA); 
Max. 40% 
inhibition [54] (BA) 
Alam-4b 
 
IC50 = 7.3 [58] (TA) 
ISO-66 
 




IC50 = 0.75 [60] 
(TA); 








Dziedzic-3bb: Ki = 
0.057 [61] (TA) 
 
Cisneros-3i: Ki = 
0.057 [62] (TA); Kd 
= 0.071 [62] (BA) 
Cisneros-3j 
 
Ki = 0.034 [62] 












Table 2. Covalent MIF inhibitors and MIF inhibitors with other structures 
Abbreviations: TA, tautomerase assay; BA, binding assay MIF-CD74. 







IC50 = 0.2–0.5 [63] (TA) 
Isothiocyanate BITC 
 
IC50 = 0.79 [65] (TA) 
Benzoxazinone NVS-2 
 
IC50 = 0.020 [69] (TA); Ki = 







IC50 = 0.01 [70] (TA) 
Pyrimidazole K664-1 
 
IC50 = 0.11 [73] (TA); Ki = 





IC50 = 6.81 [72] (TA) 
Kok-10 
 
IC50 = 18 [74] (TA) 
Kok-17 
 




2–10-fold more potent than 
ISO-1 [44] (TA) 
CPSI-1306 
 
100-fold more potent than 
ISO-1 [44] (TA) 
Isocoumarin SCD-19 
 
100% inhibition at 
concentration of 100 µM 
[46] (TA) 
AC
CE
PT
ED
 M
AN
US
CR
IPT
